Form 4 for SLDB Solid Biosciences Inc.
Accepted 2024-01-12 00:00:00 ET · period of report 2024-01-11 · accession 0000950170-24-004276 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-01-12 | 2024-01-11 | SLDB | Koppel Adam | Dir, 10% | A - Grant | $5.53 | +904.2K | 4.03M | +29% | +$5.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-11 | A | A | 904,160 | $5.53 | 4,034,582 | I See footnotes | — | — | (F2) Represents shares of Common Stock held by BCLS SB Investco, LP ("BCLS SB"), Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), BCLS II Investco, LP ("BCLS II Investco"), BCLS II Equity and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS SB, BCLS Fund II, BCLS II Investco and BCLS II Equity, the "Bain Capital Life Sciences Entities"). Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS SB, BCLS Fund II, BCLS II Investco and BCLS II Equity and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Koppel is a Partner of BCLSI. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |